cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Janux Therapeutics Inc
1 own
2 watching
Current Price
$9.04
$0.31
(3.55%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
408.95M
52-Week High
52-Week High
23.64000
52-Week Low
52-Week Low
5.65000
Average Volume
Average Volume
0.12M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization408.95M
icon52-Week High23.64000
icon52-Week Low5.65000
iconAverage Volume0.12M
iconDividend Yield--
iconP/E Ratio--
What does the Janux Therapeutics Inc do?
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company s lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Read More
How much money does Janux Therapeutics Inc make?
News & Events about Janux Therapeutics Inc.
Zolmax
8 months ago
Wedbush assumed coverage on shares of Janux Therapeutics (NASDAQ:JANX Get Rating) in a report issued on Wednesday morning, The Fly reports. The firm issued an outperform rating and a $24.00 price objective on the stock. Other equities research analysts have also issued research reports about the ...
Ticker Report
8 months ago
Wedbush initiated coverage on shares of Janux Therapeutics (NASDAQ:JANX Get Rating) in a research report report published on Wednesday, The Fly reports. The brokerage issued an outperform rating and a $24.00 target price on the stock. Several other research analysts have also commented on ...
Business Wire
9 months ago
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today...
Business Wire
11 months ago
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today...
Market News Video
1 year ago
In trading on Thursday, shares of Janux Therapeutics Inc (JANX) crossed above their 200 day moving average of 13.95, changing hands as high as 14.07 per share. Janux Therapeutics Inc shares are currently trading down about 0.1% on the day...
Frequently Asked Questions
Frequently Asked Questions
What is Janux Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Janux Therapeutics Inc shares?
plus_minus_icon
How can I buy Janux Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Janux Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Janux Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Janux Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Janux Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Janux Therapeutics Inc?
plus_minus_icon
What percentage is Janux Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Janux Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.04
$0.31
(3.55%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00